Robbie Stevens initiates coverage:
biz.yahoo.com
Friday January 22, 10:45 am Eastern Time
Company Press Release
SOURCE: BancBoston Robertson Stephens
BancBoston Robertson Stephens Initiates Coverage of Sepracor, Inc., With a Long-Term Attractive Rating
SAN FRANCISCO, Jan. 22 /PRNewswire/ -- The following is being issued by BancBoston Robertson Stephens, a member of the National Association of Securities Dealers, CRD number 41271:
BancBoston Robertson Stephens senior emerging pharmaceutical analyst Donald B. Ellis today initiated coverage of Sepracor, Inc. (Nasdaq: SEPR - news) with a Long-Term Attractive rating. Sepracor, headquartered in Marlborough, Mass., is a specialty pharmaceutical company that develops improved chemical entity (ICE) versions of currently marketed and development-stage pharmaceuticals using its chiral chemistry and active metabolite technology.
''We are initiating coverage of Sepracor with a Long-Term Attractive ratings and a 12-month price target of $112,'' said Ellis. ''The company should represent a core holding in a growth healthcare portfolio and recommend building positions on weakness.
''Sepracor's prowess in chiral and metabolite chemistry has produced multiple meaningful partnerships within the major pharma industry. Sepracor has two approved drugs and six drugs in late phase clinical development, representing approximately $6.5 billion in annual sales,'' said Ellis.
''We believe Sepracor represents a favorable risk-reward opportunity, as billion dollar drugs are developed at minimal time and cost, compared with drug discovery,'' said Ellis. ''The company's technology has been well appreciated by the Street, with increases of 141 percent and 120 percent for 1997 and 1998, respectively. The technology offers significant advantages, including, increased potency and decreased toxicity, and may also provide new indications, in our opinion.''
Clients interested in receiving more information should contact their salesperson at 415-781-9700.
BancBoston Robertson Stephens is a leading international investment banking firm focused on emerging growth companies. The firm's 55 senior research analysts cover over 575 companies. Additional information is available upon request. |
